Featured Research

from universities, journals, and other organizations

Major variation in bladder cancer subtype trends highlights need for focused research

Date:
January 9, 2012
Source:
Wiley-Blackwell
Summary:
A major study of 128,000 patients has found significant differences between the most common cancer tumors growing inside and on the surface of the bladder. Papillary transitional cell carcinoma rose by 56% between 1973 and 2007 and non-papillary transitional cell carcinoma fell by 53% over the same period, suggest that they may be two disease entities with different causes. This significant finding underlines the importance of future research differentiating between these two subtypes.

Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of the disease.

A major study of nearly 128,000 American bladder cancer cases, published in the January edition of the urology journal BJUI, shows that bladder cancer rates showed a 9% overall decrease between 1973 and 2007.

However, when the researchers looked at the two main subtypes, which accounted for 94% of the bladder tumours, they found that papillary transitional cell carcinoma (PTCC) increased by 56% over that period and non-papillary transitional cell carcinoma (NPTCC) fell by 53%.

"These two subtypes of bladder cancer are normally categorised as a single disease called transitional cell carcinoma in research studies, but our findings highlight major trend differences over more than three decades" says lead author Dr Yawei Zhang, from the School of Public Health and School of Medicine at Yale University, USA.

"This is a significant finding that underlines the importance of future research differentiating between these two subtypes."

Bladder cancer is the fifth most common cancer in the USA and is responsible for approximately 70,000 new cases and 15,000 deaths a year. Cigarette smoking and occupational exposure to arylamines -- organic chemicals -- is thought to account for more than half of the cases in the USA.

The research team used the National Cancer Institute's Surveillance and Epidemiology and End Results data for 1973-2007 to analyse trends in bladder cancer by subtype, disease stage and grade. This revealed the different trends between papillary tumours, that grow on the outside surface of the bladder, and non-papillary tumours, that grow on the inside of the bladder.

Key findings of the study included:

  • The statistics covered 127,614 first primary bladder cancer cases. The majority of the patients (74%) were male and white (92%). Nearly two-thirds of the tumours (65%) were PTCC and 29% were TCC. The other 6% included squamous cell, adenocarcinoma and small cell carcinoma.
  • The overall age-adjusted incidence rates for bladder cancer fell by about 9% between 1973 and 2007 from 16.7 per 100,000 to 15.2. Similar trends were noted in both genders and racial groups.
  • However, significant differences emerged when the research team looked at the two main subtypes. While the age-adjusted rates for NPTCC fell by about 53%, from 7.9 per 100,000 in 1973 to 3.7 per 100,000 in 2007, PTCC increased by 56% from 6.8 to 10.6 per 100,000 over the same period. Similar trends were noted in both genders and racial groups and in different stages of the disease -- localised, regional and distant.
  • A dramatic increase in the incidence rates of grade four tumours was found between 1998 and 2007, with decreasing trends for grade one, two and three tumours. This is probably due to changes in the grading system introduced in 1998, but the lack of reduction in more aggressive bladder cancer is of great concern. Similar increases were observed for NPTCC and PTCC, genders, racial groups and different disease stages.

"The striking differences in the trends between PTCC and NPTCC suggest that they may be two disease entitles with different causes" concludes Dr Zhang. "Recent survival analysis has also shown that survival rates are substantially higher for PTCC than NPTCC.

"Despite this, no epidemiological studies have investigated the risk factors of these two subtypes separately. Our study suggests that future research must make clear distinctions between PTCC and NPTCC and not just treat them as subtypes of transitional cell carcinoma."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yawei Zhang, Cairong Zhu, Maria Paula Curado, Tongzhang Zheng, Peter Boyle. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU International, 2012; 109 (1): 52 DOI: 10.1111/j.1464-410X.2011.10283.x

Cite This Page:

Wiley-Blackwell. "Major variation in bladder cancer subtype trends highlights need for focused research." ScienceDaily. ScienceDaily, 9 January 2012. <www.sciencedaily.com/releases/2012/01/120104111719.htm>.
Wiley-Blackwell. (2012, January 9). Major variation in bladder cancer subtype trends highlights need for focused research. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2012/01/120104111719.htm
Wiley-Blackwell. "Major variation in bladder cancer subtype trends highlights need for focused research." ScienceDaily. www.sciencedaily.com/releases/2012/01/120104111719.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins